Clinics in Dermatology
Volume 30, Issue 1 , Pages 34-37 , January 2012

Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid)

References 

  1. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138:370–379
  2. Chan LS, Yancey KB, Hammerberg C, et al. Immune-mediated subepithelial blistering diseases of mucous membranes. Pure ocular cicatricial pemphigoid is a unique clinical and immunopathological entity distinct from bullous pemphigoid and other subsets identified by antigenic specificity of autoantibodies. Arch Dermatol. 1993;129:448–455
  3. Domloge-Hultsch N, Gammon WR, Briggaman RA, et al. Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease. J Clin Invest. 1992;90:1628–1633
  4. Rashid KA, Gurcan HM, Ahmed AR. Antigen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol. 2006;2631–2636
  5. Bhol KC, Colon JE, Ahmed AR. Autoantibody in mucous membrane pemphigoid binds to an intracellular epitope on human beta 4 integrin and causes basement membrane zone separation in oral mucosa in an organ culture model. J Invest Dermatol. 2003;120:701–702
  6. Lazarova Z, Hsu R, Briggaman RA, et al. Fab fragments directed against laminin 5 induce subepidermal blisters in neonatal mice. Clin Immunol. 2000;95:26–32
  7. Chan LS, Vanderlugt CJ, Hashimoto T, et al. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol. 1998;110:103–109
  8. Chan LS, Soong HK, Foster CS, et al. Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome. JAMA. 1991;266:1543–1546
  9. Olsen KE, Holland EJ. The association between ocular cicatricial pemphigoid and rheumatoid arthritis. Cornea. 1998;17:504–507
  10. Chan LS, Majmudar AA, Tran HH, et al. Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid. J Invest Dermatol. 1997;108:848–853
  11. Mobini N, Nagarwalla N, Ahmed AR. Oral pemphigoid. Subset of cicatricial pemphigoid?. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85:37–43
  12. Ahmed AR, Foster S, Zaltas M, et al. Association of DQw7 (DQB1⁎0301) with ocular cicatricial pemphigoid. Proc Natl Acad Sci U S A. 1991;88:11579–11582
  13. Chan LS, Hammerberg C, Cooper KD. Significantly increased occurrence of HLA-DQB1⁎0301 allele in patients with ocular cicatricial pemphigoid. J Invest Dermatol. 1997;108:129–132
  14. Setterfield J, Theron J, Vaughan RW, et al. Mucous membrane pemphigoid: HLA-DQB1⁎0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production. Br J Dermatol. 2001;145:406–414
  15. Chan LS. In: Blistering skin diseases. Washington, DC: Manson Publishing & AMS Press; 2009;p. 56
  16. Schmidt E, Meyer-Ter-Vehn T, Zillikens D, et al. Mucous membrane pemphigoid with ocular involvement. Part I. Clinical manifestations, pathogenesis, and diagnosis. Ophthalmologe. 2008;105:285–297
  17. Messmer EM, Hintschich CR, Partscht K, et al. Ocular cicatricial pemphigoid. Retrospective analysis of risk factors and complications. Ophthalmologe. 2000;97:113–120
  18. Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet. 2001;357:1850–1851
  19. Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology. 2010;117:861–869
  20. Schumann T, Schmidt E, Booken N, et al. Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab. Acta Derm Venereol. 2009;89:101–102
  21. Ross AH, Jaycock P, Cook SD, et al. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br J Ophthalmol. 2009;93:421–422
  22. Ciralsky J, Papaliodis GN, Foster CS, et al. Keratoprothesis in autoimmune disease. Ocul Immunol Inflamm. 2010;18:275–280
  23. Dart J. Cicatricial pemphigoid and dry eye. Semin Ophthalmol. 2005;20:95–100
  24. Malik M, Gurcan HM, Christen W, et al. Relationship between cancer and oral pemphigoid patients with antibodies to alpha6-integrin. J Oral Path Med. 2007;36:1–5
  25. Letko E, Gurcan HM, Papaliodis GN, et al. Relative risk for cancer in mucous membrane pemphigoid associated with antibodies to beta4 integrin subunit. Clin Exp Dermatol. 2007;32:637–641
  26. Saw VP, Dart RJ, Galatowicz G, et al. Tumor necrosis factor-alpha in ocular mucous membrane pemphigoid and its effect on conjunctival fibroblasts. Invest Ophthalmol Vis Sci. 2009;50:5310–5317
  27. Sacher C, Rubbert A, König C, et al. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol. 2002;46:113–115
  28. Canizares MJ, Smith DI, Conners MS, et al. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol. 2006;142:1457–1461
  29. John H, Whallett A, Quinlan M. Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-alpha. Eye (London). 2007;21:1434–1435

PII: S0738-081X(11)00083-6

doi: 10.1016/j.clindermatol.2011.03.007

Clinics in Dermatology
Volume 30, Issue 1 , Pages 34-37 , January 2012

Article Tools

* Image Usage & Resolution